Quick Comparison
| HCG | SLU-PP-332 | |
|---|---|---|
| Half-Life | 24-36 hours | Estimated several hours (limited pharmacokinetic data) |
| Typical Dosage | TRT support: 250-500 IU subcutaneous two or three times weekly. PCT: 1000-2000 IU subcutaneous every other day for 2-3 weeks. Fertility: physician-directed, typically 1000-2000 IU intramuscular two or three times weekly. | Preclinical only: mouse studies used 25-50 mg/kg oral. No established human dosing protocol. Very early stage compound with no human trials conducted. |
| Administration | Subcutaneous or intramuscular injection | Oral or injection (preclinical only) |
| Research Papers | 30 papers | 1 papers |
| Categories |
Mechanism of Action
HCG
Human Chorionic Gonadotropin is a glycoprotein hormone composed of two non-covalently linked subunits: an alpha subunit (92 amino acids, shared with LH, FSH, and TSH) and a unique beta subunit (145 amino acids) that confers biological specificity. HCG's beta subunit shares approximately 85% amino acid homology with the LH beta subunit, allowing HCG to bind and activate the LH/CG receptor (LHCGR) on Leydig cells in the testes with equal or greater affinity than LH itself.
LHCGR is a Gs-coupled GPCR that activates adenylyl cyclase upon ligand binding, increasing intracellular cAMP. cAMP activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). Phosphorylated StAR transports cholesterol from the outer to the inner mitochondrial membrane — the rate-limiting step in steroid hormone synthesis. Inside the mitochondria, the cholesterol side-chain cleavage enzyme (CYP11A1) converts cholesterol to pregnenolone, which then undergoes a series of enzymatic conversions (through the delta-4 or delta-5 pathway) to produce testosterone. This entire steroidogenic cascade occurs within Leydig cells and produces intratesticular testosterone concentrations 50-100 times higher than serum levels — essential for spermatogenesis in the adjacent seminiferous tubules.
HCG's longer half-life compared to LH (24-36 hours vs 20 minutes) is due to its heavily glycosylated beta subunit, which reduces renal clearance. This extended duration makes it practical for intermittent injection protocols. In addition to stimulating testosterone, HCG activates aromatase (CYP19A1) in Leydig cells, converting some of the produced testosterone to estradiol — which is why HCG use can elevate estrogen levels, potentially causing gynecomastia and water retention. HCG also maintains Sertoli cell function (which supports spermatogenesis) through indirect paracrine signaling from testosterone-producing Leydig cells. The physical preservation of testicular volume during TRT is a direct result of maintained Leydig cell activity and seminiferous tubule function.
SLU-PP-332
SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.
SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.
The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.
Risks & Safety
HCG
Common
breast tissue growth in men (from conversion to estrogen), water retention, headache, mood swings, acne.
Serious
can speed up growth of hormone-sensitive cancers (prostate, breast); with prolonged use, the testes can stop responding; in women, can cause dangerous overstimulation of the ovaries.
Rare
blood clots, allergic reactions.
SLU-PP-332
Serious
no human safety data exists, potential off-target effects on estrogen-responsive tissues and metabolic pathways are entirely unstudied.
Full Profiles
HCG →
A hormone your body makes during pregnancy that acts like the hormone that tells the testes to produce testosterone and sperm. Used to treat low testosterone and fertility issues. Commonly used by men on testosterone therapy to keep their testes working and sperm production going, and by bodybuilders after steroid cycles to help their hormones recover.
SLU-PP-332 →
A compound developed at Washington University that activates estrogen-related receptor alpha. A next-generation exercise mimetic that enhances endurance and promotes slow-twitch muscle fiber transformation through a different mechanism than AICAR. Activates the same gene programs that endurance training induces, including mitochondrial growth and fat-burning metabolism.